NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Hunter Gillies, MBChB

Hunter has been developing treatments for patients with pulmonary hypertension for more than two decades. He has designed and executed Phase 2 and Phase 3 programs for cardiopulmonary diseases resulting in the approval of multiple drugs for pulmonary arterial hypertension. His work helped establish the current dual combination therapy used as the frontline standard of care in PAH.